Healthcare
China's CF PharmTech raises $50m Series F
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
China's Gan & Lee Pharmaceuticals gains after A-share debut
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR to buy control of Indian pharma player
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.
Medical devices: Proceed with caution
Medical devices has become a difficult place to invest but potentially all the more rewarding for those willing to take the plunge. Asia is in a prime position globally
PE-backed Hygeia completes $286m Hong Kong IPO
Chinese radiotherapy business Hygeia Healthcare, which counts Warburg Pincus, Boyu Capital, and CITIC Capital among its investors, raised HK$2.22 billion ($286.4 million) in its Hong Kong IPO.
China healthcare IPOs: Good prognosis?
There has been a steady stream of China healthcare IPOs - most of them drug developers - on the domestic, Hong Kong and US bourses in recent months. They might be benefiting from a COVID-19 tailwind but it won't be permanent
Carlyle to buy 20% of Piramal's India pharma business
The Carlyle Group has agreed to invest approximately $490 million for a 20% stake in pharmaceutical division of India’s Piramal Enterprises, which has interests ranging from outsourced drug development to an ophthalmology joint venture with Allergan.
Deal focus: Carlyle pursues largest India animal healthcare deal
The Carlyle Group is willing to invest as much as $210 million in SeQuent Scientific to get a head start in India's rapidly evolving animal healthcare industry
General Atlantic invests $100m in Chinese drug maker
General Atlantic has invested $100 million in NASDAQ-listed Chinese cancer drug developer Hutchison China MediTech - also known as Chi-Med - a subsidiary of Hong Kong conglomerate CK Hutchison Holdings.
VC-backed SinocellTech enjoys strong Star Market debut
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
China's Genetron trades flat after upsizing US IPO
Genetron Holdings, a Chinese company that uses DNA sequencing to support the diagnosis and treatment of cancer, traded flat on its NASDAQ debut following a larger-than-planned $256 million IPO.
China's Miaoshou Doctor raises $85m
Miaoshou Doctor, a Chinese online healthcare services platform, has raised RMB600 million ($85 million) in the first tranche of Series D funding round backed by the likes of Qiming Venture Partners, Sequoia Capital China, Ince Capital Partners, CITIC...
BOC leads Series B-plus for Chinese AI player Shukun
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the diagnosis of cardiovascular diseases, has raised RMB200 million ($28 million) in an extended Series B round led by BOC International and CCB International.
BGH buys health centers from Australia's Healius for $341m
BGH Capital has agreed to acquire the primary care business of Australia’s Healius – comprising medical centers, GP practices, and dental clinics – for an enterprise valuation of A$500 million ($341 million).
China's Burning Rock soars on debut after $222m US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, rose 49% on its trading debut following a $222.8 million US IPO.
CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
CVC seeks control of India healthcare player HCG
CVC Capital Partners is looking to acquire majority control of Indian cancer care center operator HealthCare Global Enterprises (HCG) in a deal that could be worth up to IN10.4 billion ($$138.9 million).
Chinese drug developer Everest secures $310m Series C
Everest Medicines, a China-based biopharmaceutical company, has raised $310 million in Series C funding across two tranches.
Deal focus: IMM overcomes distancing disruption
Health and safety was a priority when IMM Private Equity negotiated a $413 million carve-out of Korea Kolmar Holdings' drug outsourcing business against the backdrop of COVID-19
Hillhouse leads $160m Series B for China's Genor Biopharma
Genor Biopharma, a Shanghai-based innovative drug developer, has raised $160 million in Series B funding led by Hillhouse Capital.
Shiyu leads $276m round for China's Mabwell Biotech
Mabwell Biotech, a Chinese drug developer with one treatment cleared for production, has raised RMB1.97 billion ($276 million) in Series A funding across two tranches led by specialist healthcare investor Shiyu Capital.
Sequoia leads $30m round for China's Atom Bioscience
Chinese drug developer Jiangsu Atom Bioscience & Pharmaceutical has raised $30 million in Series B funding led by Sequoia Capital China and Hong Kong-listed Livzon Pharmaceutical Group.
MGI Tech closes China's largest-ever genetics funding round
MGI Tech, a Chinese manufacturer of gene sequencing devices, has raised more than $1 billion in funding led by IDG Capital and CPE.
IMM agrees $413m Korea pharma acquisition
IMM Private Equity has agreed to acquire Korea Kolmar Holdings’ pharmaceutical contract development and manufacturing organization (CDMO) for KRW512.5 billion ($413 million).
